Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus ZADITOR.
CLARITIN REDITABS vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
10 mg orally once daily.
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine
Antihistamine